| Literature DB >> 32421016 |
Burranboina Kiran Kumar1, K M Kumar1,2, G B Manjunatha Reddy3, Sunil Abraham4, R Yogisharadhya3, C N Prashantha1.
Abstract
Viral-like particles are assembled from capsid protein structural subunits of different viruses and have ability to establish research in biomedicals, like construction of novel safety vaccines, gene therapy vectors by delivering systems for nucleic acids, small biomolecules and diagnostics. Papaya Mosaic Viral nanoparticals can provide as a vaccine candidate helps to increase the immunity by fusing the epitope based peptide antigen. Capripox viruses are the genus comprises Lymphy skin-disease, Sheep and Goat pox Viruses are notified by The World Animal Health Organization (OIE) based on their economic impotence act as a transboundary animal diseases viruses of sheep, goat, and cattle's respectively. Plant viral based innovative vaccines have been emerged ineffective vaccine development. This research describes the engineering and development of a new vaccine candidate by display immunogenic peptide using the carrier capsid protein of Papaya Mosaic Virus. The Capripox virus P32 immunogenic protein is homologous of the vaccinia virus H3L gene displayed PapMV CP. The antigenicity of P32 protein epitope lowest score among epitopes C-terminally docked epitopes are EP6 > EP3 > EP8 as well the lowest score among epitopes N-terminally docked epitopes are EP8 > EP3 > EP6 presented on the N-terminus of PMV CP region which are found to be suitable for epitope display. And these modelled immunogenic peptide could be used to develop a viral like particles. Epitope based Antibody developed against immunogenic epitopic regions can contribute to a novel and robust protection from infection. As well might be used for developing cost effective detection kits for Transboundary animal disease viruses. © Springer Nature B.V. 2020.Entities:
Keywords: B-Cell epitopes; Capripox viruses; Papaya mosaic viral capsid protein; Viral-like particles
Year: 2020 PMID: 32421016 PMCID: PMC7222904 DOI: 10.1007/s10989-019-10007-4
Source DB: PubMed Journal: Int J Pept Res Ther ISSN: 1573-3149 Impact factor: 1.931
Parameters computed using Expasy’s ProtParam tool
| Property | Values of P32 major envelope protein | PMV CP | ||
|---|---|---|---|---|
| Sheeppox virus | Goatpox virus | Lumpy skin disease virus | ||
| Number of amino acides | 323 | 322 | 322 | 215 |
| Molecular weight | 37583.58 | 37474.57 | 37593.62 | 23033.09 |
| Theoretical pl | 8.24 | 8.84 | 8.24 | 7.73 |
| Total number of negatively charged residues(Asp+Glu) | 38 | 36 | 38 | 15 |
Total number of positively residues (Arg+Lys) | 40 | 41 | 40 | 16 |
| Extinction coefficient (1.330, assuming all pairs of Cys residues form cystines) | 49975 | 51465 | 49975 | 17085 |
| Extinction coefficient* (1.326, assuming all Cys residues are reduced) | 49850 | 51340 | 49850 | 16960 |
| Instability index | 28.63 | 26.49 | 28.18 | 46.37 |
| Aliphatic index | 103.81 | 100.78 | 102.61 | 72.28 |
| Grand average of hdropathicity | − 0.041 | − 0.042 | − 0.03 | − 0.148 |
Fig. 1Multiple sequence alignment of P32: Multiple sequence alignment of P32 from 11 different strains of Capripox viruses were tested by T-Coffee program (https://tcoffee.crg.cat/apps/tcoffee/do:regular). Among all selected capripox viral p32 sequences colured regions in the above alignment showen perfect sequence alignment. And the predicted epitopes were marked as boxes in the particular regions
Fig. 2Modelled and validated Papaya Mosaic Viral Coat Protein Pyre2 and RAMPAGE
Fig. 3Modelled and predicted structure of p32 protein and predicted different epitopic regions highlighted in different colours
Prediction and verification of P32 epitopes by VaxiJen antigen prediction server
| Epitope Sl. No | Start | End | Peptide | Number of residues | Score | VaxiJen probable antigenic score |
|---|---|---|---|---|---|---|
| Ep1 | 21 | 36 | PELKSDNDIFYKKVDT | 16 | 0.789 | 0.1976 (NP) |
| Ep2 | 66 | 94 | EKVEKSGGVENFTEYFSGLCNALCTKEAK | 29 | 0.711 | 0.3483 (NP) |
| Ep3 | 110 | 118 | ADIKNSENK | 9 | 0.688 | 0.5925 (AP) |
| Ep4 | 155 | 181 | TFHNSNSRILFNQENNNFMYSYTGGYD | 27 | 0.673 | 0.3671 (NP) |
| Ep5 | 220 | 224 | KELKL | 5 | 0.643 | – |
| Ep6 | 11 | 19 | IVGREISDV | 9 | 0.613 | 0.7832 (AP) |
| Ep7 | 199 | 210 | NEIIKNKGISTS | 12 | 0.614 | 0.2495 (NP) |
| Ep8 | 140 | 147 | IEMQEKNI | 8 | 0.526 | 1.5581 (AP) |
A probable antigen, NA probable non-antigen, NP non probable antigen, AP probable antigen
Predicted and assessment of docked complexes
| Models of PMV CP-epitope | HADDOCK score | Z-score | Van der Waals energy (Kcal mol−1) | Electrostatic energy (Kcal mol−1) | Desolvation energy (Kcal mol−1) | Restraints violation energy (Kcal mol−1) | Buried surface area | |
|---|---|---|---|---|---|---|---|---|
| Coat protein terminal | Epitope name | |||||||
| Carboxy terminal (C) | EP3 | − 55.6 ± 8.2 | − 1.7 | − 29.6 ± 1.9 | − 135.0 ± 49.1 | − 8.4 ± 4.0 | 94.2 ± 29.61 | 954.8 ± 38.8 |
| EP6 | − 62.0 ± 5.2 | − 1.4 | − 33.3 ± 4.5 | − 75.5 ± 26.4 | − 21.7 ± 1.6 | 81.8 ± 42.08 | 976.1 ± 43.6 | |
| EP8 | − 52.4 ± 2.4 | − 1.4 | − 24.9 ± 8.9 | − 117.8 ± 25.4 | − 13.7 ± 3.3 | 97.5 ± 31.10 | 909.0 ± 72.0 | |
| Amino terminal (N) | EP3 | − 56.7 ± 4.8 | − 1.8 | − 32.9 ± 4.3 | − 102.7 ± 30.7 | − 13.2 ± 9.6 | 98.5 ± 47.72 | 953.1 ± 84.4 |
| EP6 | − 55.4 ± 2.0 | − 1.6 | − 34.5 ± 5.7 | − 99.4 ± 35.7 | − 8.3 ± 2.6 | 72.9 ± 35.11 | 1027.6 ± 78.3 | |
| EP8 | − 57.5 ± 2.1 | − 1.9 | − 35.5 ± 1.3 | − 144.1 ± 12.9 | − 6.6 ± 4.2 | 135.0 ± 34.00 | 1024.5 ± 61.6 | |
Fig. 4PMV CP- immunogenic Capripox viral envelop P32 protein epitopes docking at N, C termini: Protein–epitope docking of P32 epitopes at N, C by using HADDOCK server and the models are displayed in surface models using PyMOL
Fig. 5Interaction between PMV CP at C-terminus regions with CEp3, CEp6 and CEp8 epitopes
Fig. 6Interaction between PMV CP at N-terminus regions with NEp3, NEp6 and NEp8 epitopes
Evaluation of predicted models by Rampage
| Models of PMV CP-epitope | Number of residues in favoured region | Number of residues in allowed region | Number of residues in outlier region | |
|---|---|---|---|---|
| Coat protein terminal | Epitope name | |||
| P32 | – | 210 (98.6%) | 3 (1.4%) | 0 (0.0%) |
| PMV | – | 210 (98.6%) | 3 (1.4%) | 0 (0.0%) |
| Carboxy terminal (C) | EP3 | 204 (92.7%) | 14 (6.4%) | 2 (0.9%) |
| EP6 | 203 (92.3%) | 14 (6.4%) | 3 (1.4%) | |
| EP8 | 206 (94.1%) | 11 (5.0%) | 2 (0.9%) | |
| Amino terminal (N) | EP3 | 209 (95.0%) | 10 (4.5%) | 1 (0.5%) |
| EP6 | 198 (90.0%) | 20 (9.1%) | 2 (0.9%) | |
| EP8 | 208 ( 95.0%) | 10 (4.6%) | 1 (0.5%) | |
Interaction between PMV CP at C-terminus regions with CEp3, CEp6 and CEp8 epitopes
| Protein chain A T O M 1 | Epitope chain A T O M 2 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CEp3 | Atom no | Atom name | Res name | Res no | Chain | Atom no | Atom name | Res name | Res no | Chain | Distance | |
| 1 | 1830 | O | LYS | 198 | A | < – | 2028 | OG | SER | 6 | B | 3.25 |
| 2 | 1836 | N | GLN | 200 | A | – > | 1999 | O | ILE | 3 | B | 3.03 |
| 3 | 1864 | O | SER | 202 | A | < – | 2007 | NZ | LYS | 4 | B | 2.87 |
| 4 | 1877 | O | SER | 204 | A | < – | 2007 | NZ | LYS | 4 | B | 2.67 |
| 5 | 1874 | OG | SER | 204 | A | < – | 2007 | NZ | LYS | 4 | B | 2.9 |
| 6 | 1893 | O | PRO | 206 | A | < – | 2048 | ND2 | ASN | 8 | B | 3.18 |
| 7 | 1972 | OE1 | GLU | 215 | A | < – | 2060 | NZ | LYS | 9 | B | 2.65 |
Interaction between PMV CP at N – Terminus regions with NEp3, NEp6 and NEp8 Epitopes
| Protein chain A T O M 1 | Epitope chain A T O M 2 | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NEp3 | Atom no | Atom name | Res name | Res no | Chain | Atom no | Atom name | Res name | Res no | Chain | Distance | |
| 1 | 30 | O | LYS | 3 | A | < – | 2060 | NZ | LYS | 9 | B | 2.68 |
| 2 | 68 | OG1 | THR | 8 | A | – > | 1987 | OD1 | ASP | 2 | B | 2.63 |
| 3 | 68 | OG1 | THR | 8 | A | < – | 2019 | ND2 | ASN | 5 | B | 2.96 |
| 4 | 86 | ND2 | ASN | 10 | A | – > | 2031 | O | SER | 6 | B | 2.67 |
| 5 | 86 | ND2 | ASN | 10 | A | – > | 2052 | O | ASN | 8 | B | 2.8 |
| 6 | 139 | O | ILE | 16 | A | < – | 1982 | N | ASP | 2 | B | 2.95 |
| 7 | 139 | O | ILE | 16 | A | < – | 1991 | N | ILE | 3 | B | 2.94 |
| 8 | 155 | OE1 | GLN | 18 | A | < – | 2007 | NZ | LYS | 4 | B | 2.88 |